BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Gilead Sciences

There are several pluses for BioNTech in the deal.

Why Investors Should Like BioNTech's Latest Deal With Gilead

There was more good news for the company's COVID-19 vaccine.

Why BioNTech Stock Jumped This Week

Moderna

Millions of Americans still really, really don't want to get vaccinated.

Why Moderna and BioNTech Slipped Today

Pfizer

Israeli health officials said they've seen protection against severe illness from Pfizer's vaccine decrease from 97% to 81% over time.

Israel will roll out a booster dose of the Pfizer-BioNTech COVID-19 vaccine to older people, citing a drop in protection against severe disease driven by the Delta variant

Bioline RX

Canadian Solar

Danaos

Global Ship Lease

Jumia

Goldman Sachs JUST US Large Cap Equity ETF

Lithium Americas Corp

VanEck Rare Earth/Strategic Metals ETF

SSR Mining

Universal Insurance Hlds

Viatris

Zogenix

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.

2021 Top Idea Contest - New Ideas

A confluence of COVID-19 news conspired to drive shares of the biotechnology company higher.

Why BioNTech Stock Shot Higher on Wednesday

Pfizer's vaccine initially protects people 100% of the time against hospitalization, but that falls to low 90% and mid-to-high 80% after six months, Bourla said

Pfizer's CEO says Covid vaccine effectiveness drops to 84% after six months

Based on its earnings report, Pfizer (PFE) raised estimated sales of its Covid-19 vaccine to $33.5 billion for 2021, reflecting a 30% increase as Delta sweeps through nations, reports The Wall Street Journal. The biopharmaceutical giant is one of many major players reporting profitable earnings for the last quarter as these mega-caps continue to outperform.

Pfizer Reports Positive Earnings, Raises Forecasted Sales of Vaccine

A third dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine can "strongly" boost protection against the delta variant beyond the protection afforded by the standard two doses. Pfizer's new data suggest that antibody levels against the delta variant in people ages 18 to 55 who receive a third dose of vaccine are greater than five-fold than following a second dose.

Third Dose Of Pfizer-BioNTech's COVID-19 Vaccine Boosts Protection Against Delta Variant, New Data Reveals

Pfizer Inc. (NYSE: PFE) shares were trading about 2.1% higher at $42.99 per share after the company reported better-than-expected Q2 EPS and sales results. The company also raised its full-year 2021 earnings per share guidance and sales guidance above analyst estimates.

Why Pfizer And BioNTech Shares Are Moving Higher Today

Pfizer said Wednesday it is raising the 2021 sales forecast of its Covid-19 vaccine to $33.5 billion from $26 billion.

Pfizer sells $7.8 billion in Covid shots in the Q2, raises 2021 guidance on vaccine sales

(Reuters) -Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany's BioNTech by 28.8% to $33.5 billion, as countries scramble to secure supply of the shots.

Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 billion

AC Immune

AC Immune SA (NASDAQ: ACIU) has gained a multi-million investment from the principal backers of BioNTech SE (NASDAQ: BNTX) while acquiring a possible Parkinson's disease vaccine. It announced a $25 million private share placement with a group of investors led by Athos Service GmbH.

AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine Candidate

BioNTech entered 2020 as a well-respected — if a bit under-the-radar — biotech company. A little more than a year later, the firm is.

After Covid, BioNTech Has Its Sights Set on Malaria

The company is gearing up for a big fight against another high-profile disease.

Why BioNTech Rose as Much as 5% Today

The German pharmaceutical group behind one of the most successful COVID-19 vaccines wants to use the same technology to develop a malaria vaccine.

BioNTech using COVID jab technology to develop effective malaria vaccine

The studies aim to spot rare side effects of the COVID-19 vaccine in younger recipients.

Pfizer and Moderna expanding vaccine studies in children 5 to 11, report says

The vaccine makers were reportedly asked by the Food and Drug Administration to expand the size of their ongoing trials.

Pfizer And Moderna Reportedly Expanding Covid Vaccine Studies Of Children To Better Understand Rare Side Effects

Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) will expand the size of ongoing COVID-19 vaccine trials in children ages five to 11 to detect potential rare side effects, The New York Times reports. What Happened: The trial expansions come at the urging of the FDA, a precautionary measure designed to detect rare side effects, including heart inflammation problems that turned up in vaccinated people younger than 30.

FDA Asks Pfizer/BioNTech, Moderna To Expand COVID-19 Vaccine Trials In Children: NYT

In terms of hospitalisation and death, COVID is becoming a pandemic of the unvaccinated. Achieving herd immunity is critical not only for reopening economies but also to mitigate long-term chronic health problems from those recovered from COVID.

Pfizer/BioNTech COVID Vaccine(s) And The Future

Citi's Andrew Baum also thinks chances are good that annual boosters will be needed, even if risk of the disease drops.

Covid Boosters Are Coming This Year for People 50 and Older, Analyst Predicts

BioNTech said it plans to develop a highly effective mRNA-based vaccine to prevent malaria, a life-threatening disease that impacts millions of people worldwide each year.

BioNTech says it plans to develop an mRNA vaccine to prevent malaria

MAINZ, Germany, July 26, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced the launch of its Malaria project, which aims to develop a well-tolerated and highly effective Malaria vaccine and implement sustainable vaccine supply solutions on the African continent.

BioNTech Provides Update on Plans to Develop Sustainable Solutions to Address Infectious Diseases on the African Continent

Novavax

Owens & Minor

Despite sizzling year-to-date gains, these stocks are surprisingly inexpensive.

3 Red-Hot Stocks That Are Still Dirt Cheap

The federal government has bought an additional 200 million COVID-19 vaccine doses that are expected to be delivered starting in October 2021.

News for BioNTech SE Stock (BNTX)